Results of multi-center, matched retrospective analysis
demonstrates Ceribell point-of-care EEG monitoring is associated
with four day shorter ICU length of stay on average, and fewer
patients leaving the ICU with disabilities, compared to
conventional EEG.
SUNNYVALE, Calif., July 23,
2024 /PRNewswire/ -- Ceribell, Inc., a
commercial-stage medical technology company focused on transforming
the detection and management of patients with serious neurological
conditions, today announced the publication of results from a new
multi-center retrospective study of patient outcomes following use
of the Ceribell system compared to conventional
electroencephalography ("EEG"). Study findings associated the use
of Ceribell with a significant reduction in length of stay in the
ICU, fewer patients discharged with poor functional disability
scores, and - as expected - faster door-to-EEG time compared to
conventional EEG.1 The study was published in
Neurocritical Care, the journal of
the Neurocritical Care
Society.
"Ceribell use is associated with shorter stays in the ICU
and better functional outcomes, which are extremely impactful
benefits to patients and their families," said principal
investigator Masoom J. Desai, MD,
FACNS, Assistant Professor, Department of Neurology at the
University of New Mexico School of
Medicine.
Key findings based on study objectives:
- 4.1 days shorter median ICU length of stay
with Ceribell vs. conventional EEG
- 18 percentage point decrease in the rate of patients
discharged with poor modified Rankin Scale scores
(an indicator of functional disability) when patients were
assessed with Ceribell vs. conventional EEG
- 19 hours faster median time to EEG acquisition with
the Ceribell System; 5.9 hours with Ceribell vs.
25.3 hours with conventional EEG
The study is a propensity score matched sub-analysis of
283 patient records from the SAFER-EEG trial, a retrospective study
of adult patients monitored with EEG during a hospital stay. The
publication adds to a robust body of research highlighting the
significant delays to conventional EEG across hospitals in the U.S.
and validates the clinical and economic benefits of the Ceribell
system for the detection of non-convulsive seizures and management
of patients at risk of non-convulsive status epilepticus in the
acute care setting.
"These study results underscore the critical need for
early assessment with point-of-care EEG, and the ability for
providers to improve patient care while reducing length of stay and
strain on hospital personnel through use of the Ceribell system,"
said Jane Chao, Ph.D., Ceribell
Co-founder and Chief Executive Officer. "The meaningful association
between frontline access to Ceribell's point-of-care EEG and
improved patient outcomes will continue to drive our commitment to
revolutionizing neurodiagnostics."
The primary SAFER-EEG study was conducted at 4 top-tier
academic hospitals in the United
States. Results were recently published in
Neurology,2
and demonstrate that Ceribell point-of-care EEG performs
comparably to conventional EEG in forecasting seizure risk for
acutely ill patients using the 2HELPS2B score.
Contact us to schedule a demo and experience
how Ceribell point-of-care EEG transforms patient care.
About the Ceribell System
The Ceribell system is a novel, point-of-care EEG platform
designed to address the unmet neurodiagnostic needs of patients in
the acute care setting. By combining proprietary, highly portable,
and rapidly deployable hardware with a sophisticated AI-powered
algorithm, the Ceribell system enables rapid diagnosis and
continuous monitoring of patients with neurological conditions. The
Ceribell system is FDA 510(k) cleared for indicating suspected
seizure activity and currently utilized in intensive care units and
emergency rooms across the U.S. The Ceribell system received two
FDA Breakthrough Device Designations in 2022, and in 2023, the
latest generation of Ceribell's AI algorithm (Clarity™) made it the
first and only device to receive 510(k) clearance for
diagnosing electrographic status
epilepticus. Subsequently, the Clarity algorithm
received a New Technology Add-on Payment (NTAP) from the Centers
for Medicare and Medicaid Services (CMS).
About Ceribell
Ceribell, Inc. is a
developer of AI-powered point-of-care electroencephalography (EEG)
technology dedicated to improving the detection and treatment of
neurological conditions. Our goal is to revolutionize brain health
by making EEG diagnostics widely available, more efficient, and
more cost-effective. We are initially focused on becoming the
standard of care for the detection and management of non-convulsive
seizures in the acute care setting. Ceribell is headquartered in
Sunnyvale, Calif. For more
information, please visit
www.ceribell.com or follow the company
on LinkedIn.
MEDIA CONTACT
Corrie
Rose
press@ceribell.com
INVESTOR CONTACT
Brian Johnston or Laine
Morgan
Gilmartin Group, LLC
Brian@gilmartinir.com
Laine@gilmartinir.com
References
1. Desai, M., et al. (2024) Neurocrit
Care
2. Kalkach-Aparicio,M., et al. (2024)
Neurology.103 (2)
View original content to download
multimedia:https://www.prnewswire.com/news-releases/ceribell-announces-publication-of-study-demonstrating-significant-reduction-in-length-of-icu-stays-and-better-patient-outcomes-with-ceribell-point-of-care-eeg-compared-to-conventional-eeg-302203966.html
SOURCE Ceribell, Inc.